News
Protein Sciences Corporation News
Web Site:
http://www.proteinsciences.com
- Sanofi Pasteur Inc.
1000 Research Pkwy.,
Meriden, CT 06450
- 7159
Tel: (203) 686-0800
Fax: (203) 686-0268
Protein Sciences Corporation, founded in 1983, is a privately held vaccine company with headquarters in Meriden, Connecticut. PSC's mission is to save lives and improve health.
View all News Articles for Protein Sciences Corporation
U.S. Senate Candidate Linda McMahon Visits Protein Sciences Corporation
June 14, 2012
Leading executive and U.S. Senate candidate Linda McMahon visited Protein Sciences Corporation on Wednesday, May 30, as part of her tour of Connecticut in support of her campaign. Ms. McMahon recently claimed victory at the Connecticut Republican Convention and received the Republican Party's endorsement for the 2012 Senate election. The crux of her campaign is centered on job creation and reviving the economy in Connecticut. As a leader in recombinant vaccine manufacture, Meriden-based Protein Sciences supports this mission, having expanded our workforce by more than 20% over the past year. "We were delighted to host Linda and show her how the work we do supports both the people and economy in Connecticut," said Manon Cox, President and CEO of Protein Sciences. "The U.S. government has put a lot of trust in us by awarding us a large contract (total value of around $147 million over 5 years) for the development of a recombinant influenza vaccine that is essential to prepare the country for a potential influenza pandemic. Our location in Connecticut means that this trust gets translated into new jobs and resources for the people of our state." During Ms. McMahon's visit, she had the opportunity to tour Protein Sciences' new state-of-the-art product realization laboratory and had the chance to meet and converse with employees. About Us Protein Sciences Corporation is a vaccine development and protein production company based in Meriden, CT that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceuticals. Our proprietary baculovirus expression vector system (BEVS) technology provides a fast, reliable and inexpensive platform for the production of high quality recombinant proteins, making it a powerful tool for producing vaccines and therapeutics when they are needed most. BEVS technology is covered by broad patents that include our proprietary expresSF+® cell line that we use to make all of our products. Our lead product, FluBlok®, is a recombinant trivalent vaccine for seasonal influenza, consisting of recombinant influenza hemagglutinin (rHA) proteins that are manufactured using cell culture instead of eggs. FluBlok is highly purified, does not include thimerosal or antibiotics, and is low in endotoxins. FluBlok, which has shown exceptional performance in clinical trials, is under final review by the U.S. Food and Drug Administration. In 2009, we received a $147 million five-year contract award by the Biomedical Advanced Research and Development Authority, a division of the U. S. Department of Health and Human Services, to further develop our technology for the production of recombinant influenza vaccines for pandemic preparedness. Budgets totaling more than $80 million have thus far been approved to support work through at least mid-2013. Learn more at www.proteinsciences.com.
Member News is provided as a service of the Midstate Chamber of Commerce and is also featured in the monthly "Chamber News" newsletter mailed to members.
The “original publication date” of Member News articles posted on this web site reflects the date this article was added to the Chamber database and may not necessarily reflect the date such news events occurred.